Clinical Trial Update: Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating durvalumab in combination with endocrine therapy for ER+/HER2- breast cancer after an immune-attractant exposure; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: UNICANCER | Conditions: Breast Cancer, Estrogen Receptor Positive Tumor | Phase 2 | Status: COMPLETED